Hualan Biological Bacterin Inc.

Shenzhen Stock Exchange 301207.SZ

Hualan Biological Bacterin Inc. Debt to Equity Ratio for the year ending December 31, 2023: 0.05

Hualan Biological Bacterin Inc. Debt to Equity Ratio is 0.05 for the year ending December 31, 2023, a -12.24% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Hualan Biological Bacterin Inc. Debt to Equity Ratio for the year ending December 31, 2022 was 0.05, a -69.47% change year over year.
  • Hualan Biological Bacterin Inc. Debt to Equity Ratio for the year ending December 31, 2021 was 0.18, a 95.60% change year over year.
  • Hualan Biological Bacterin Inc. Debt to Equity Ratio for the year ending December 31, 2020 was 0.09, a 0.00% change year over year.
  • Hualan Biological Bacterin Inc. Debt to Equity Ratio for the year ending December 31, 2019 was 0.00, a 0.00% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
Shenzhen Stock Exchange: 301207.SZ

Hualan Biological Bacterin Inc.

CEO Ms. Wenjue An
IPO Date Feb. 18, 2022
Location China
Headquarters No. 1, Westlands Road
Employees 770
Sector Healthcare
Industries
Vaccines Biotechnology
Description

Hualan Biological Bacterin Inc. engages in the research, development, production, and sale of vaccines in China. It offers It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, H1N1 influenza virus split vaccines, ACYW135 meningococcal polysaccharide plague vaccines, recombinant hepatitis B vaccines, and group A and C meningococcal polysaccharide vaccines, as well as genetic engineering vaccines for human use. The company was founded in 2005 and is based in Xinxiang, China. Hualan Biological Bacterin Inc. was formerly a subsidiary of Hualan Biological Engineering Inc.

StockViz Staff

February 2, 2025

Any question? Send us an email